Roche and As­traZeneca set­tle years­long patent bat­tle over Ul­tomiris — re­port

Roche’s Chugai unit and As­traZeneca’s Alex­ion have set­tled a years­long patent bat­tle over the lat­ter’s Ul­tomiris — a rare blood dis­or­der treat­ment de­signed to suc­ceed Alex­ion’s block­buster Soliris, ac­cord­ing to re­ports.

The set­tle­ment was filed un­der seal on Mon­day, Bloomberg Law and Law 360 re­port­ed, and the terms are cur­rent­ly un­known. Alex­ion de­clined to com­ment on the case, while Chugai wasn’t avail­able as of press time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER